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Introduction
Double-stranded RNAs, such as a small interfering RNAs 
(siRNAs), induce degradation of sequence-specific homolo-
gous mRNA via RNA interference (RNAi), a mechanism of 
post-translational gene silencing. In order for an siRNA to be 
effective upon entering the cell, the siRNA must become phos-
phorylated on the 5′-end by Clp1 kinase and be incorporated 
into the endogenous RNA-induced silencing complex, which 
consists of Ago2, Dicer, and TRBP.1–5 Nucleotides 2 through 
8 of the siRNA guide strand are preassembled in an A-form 
helix and the guide strand makes contact with the surface 
of Ago2 through its sugar and phosphodiester backbone.6,7 
The guide strand can then associate with the complementary 
mRNA strand, causing consequent cleavage of the mRNA, 
and thereby regulates gene expression.
RNAi-based therapy presents an attractive opportunity to 
engage  targets  not  accessible  through  conventional  small 
molecules.8 While the activity of unmodified, all ribonucle-
otide, siRNAs are suitable for in vitro experiments, siRNA use 
in vivo requires higher standards for siRNA potency, specific-
ity, and safety that can be achieved through modifications to 
the individual nucleosides on the siRNA.9–11 Once the best 
siRNA sequence has been chosen for a target, the siRNA 
can be optimized through chemical and structural modifica-
tions.12–15 Modified siRNA duplexes are expected to reduce 
ribonuclease degradation in plasma,16 immunogenicity, the 
off-target effects from genes having sequence complemen-
tarity  to  either  siRNA  strand,  and  poor  pharmacokinetic 
properties.17–19 The chemical modifications that can poten-
tially  optimize  the  performance  of  an  siRNA  include:  the 
ribose ring to alter the sugar pucker and helical properties of 
the siRNA;20 the bases to reshape hydrogen-binding proper-
ties that target mRNA;21 or the phosphodiester backbone to 
adjust charge interactions.22
The most widely used and commercially available modifi-
cations in siRNAs have been limited to ones discovered over 
10 years ago in the antisense field and developed at the 2′ 
position  of  the  ribose  ring  including  2′-methoxy  (2′-OMe), 
2′-fluoro (2′-F), and 2′-O-methoxyethyl (2′-MOE).23 2′-OMe 
and 2′-F modifications are well tolerated at multiple positions 
in the siRNA guide strand due to their small size that is com-
parable to the natural RNA 2′-OH. They provide increased 
stability, increased specificity and reduced immunogenicity.24 
The structures of other, larger, 2′-O-modifications such as 
2′-O-MOE  and  2′-O-allyl  modifications  caused  attenuated 
silencing activity. These modifications were tolerated in only 
a very position-specific manner within the guide strand.25–28 
They appeared to cause steric clashes with Ago2 residues 
thereby preventing guide strand loading into RISC.7,28 These 
studies demonstrate that siRNA-optimized modifications are 
needed to improve siRNA activity. Even though discovery of 
chemical  modifications  that  are  beneficial  and  universally 
favorable to siRNAs in vivo have been elusive, identification, 
and design of siRNAs to achieve maximal activity will be nec-
essary for therapeutic development.9
Recently,  we  identified  a  new  siRNA  2′-O-modification, 
2′-O-benzyl,  which  was  tolerated  at  multiple  positions 
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throughout the guide strand, in contrast to what has been 
reported  previously  with  2′-MOE.29  Due  to  this  surprising 
finding, we decided to further evaluate this new modification 
for its potential to be used in RNAi therapeutics. In this study 
we evaluated, in vivo, 2′-O-benzyl, and its pyridine deriva-
tive  2′-O-methyl-4-pyridine  (2′-O-CH2Py(4)).  In  contrast  to 
the benzyl functional group, pyridine contains a set of lone 
pair electrons from the nitrogen atom which contributes to its 
shorter C-N bond length, planarity of the six-membered ring, 
and ability to hydrogen bond. We identified positions that toler-
ated these modifications and then combined these positions 
to optimize multiple siRNA sequences to demonstrate the 
applicability of these modifications to any sequence of choice. 
Combinations of four 2′-O-benzyls or six 2′-O-CH2Py(4) were 
tolerated in siRNA guide strands and had similar activity to 
unmodified siRNAs in vivo, demonstrating modifications can 
be tolerated in the guide strand and convey beneficial prop-
erties in vivo. The optimal combination that increased in vivo 
activity over unmodified siRNAs contained only two modifica-
tions, at positions 8 and 15. This study shows the importance 
of using optimized modifications specific for siRNAs and that 
placement of these new modifications is critical for obtaining 
maximal in vivo silencing activity.
Results
Novel 2′-O- modifications are tolerated at multiple posi-
tions  in  the  guide  strand.  In  order  to  determine  which 
positions  in  the  siRNA  guide  strand  to  place  2′-O-benzyl 
and  2′-O-CH2Py(4)  for  in  vivo  studies  we  first  evaluated 
them in vitro. Five different double-stranded 21-mer siRNA 
sequences  were  evaluated  in  vitro. The  gene  names  and 
start target sites are: ApoB(9514), ApoB(10162), PHD2(196), 
PHD2(384),  and  PCSK9(1965).  Positions  1–19  of  both 
strands were ribonucleotides, and the overhangs at positions 
20  and  21  contained  2′-OMe  nucleotides. The  passenger 
strands contained inverted abasics at the 5′ and 3′ ends to 
block loading into Ago2.10 siRNAs containing 2′-O-CH2Py(4) 
at position 1 also had a 5′-P but 2′-O-benzyl modifications at 
position 1 did not, which contributed to the attenuated activ-
ity for 2′-O-benzyl at that position. These unmodified siRNAs 
were the template for systematic evaluation of siRNAs con-
taining a single 2′-O-benzyl or 2′-O-CH2Py(4) modification at 
every position along the guide strand corresponding to the 
base that naturally occurs at that position (Figure 1a).
All siRNAs demonstrated target-specific mRNA degrada-
tion in cell-based assays as detected by quantitative PCR 
(qPCR).  Hepa  1-6  cells  were  transfected  with  either  an 
unmodified siRNA that had a natural 2′-OH or with an siRNA-
containing 2′-O-benzyl (Figure 1b) or 2′-O-CH2Py(4) (Figure 
1c) on the guide strand to test for maximal mRNA degrada-
tion. The data is normalized using the unmodified version of 
each sequence and taking the log2 ratio of the modified to the 
unmodified siRNA for each position, with a bar indicating the 
median. Unmodified siRNA corresponds to zero on the graph. 
If a modification has similar activity to unmodified siRNA the 
ratio value is zero (log2 of 1 is zero). If a modification attenu-
ates activity it has a negative ratio value in relationship to 
its unmodified siRNA control; if the modification increases 
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Figure 1  In vitro activity of 2′-o-benzyl and 2′-o-CH2Py (4). 
(a) Structure of the nucleotides used for oligonucleotide synthe-
sis with 2′-OH or 2′-O-benzyl (in red). Adenosine is representa-
tive of the modifications to the other bases, guanosine, cytosine 
and uracil. (b, c) mRNA degradation of target as determined by 
quantitative PCR (qPCR) and compared to unmodified. Values are 
shown as log 2 deviations from unmodified. A log ratio of 1 rep-
resents a twofold change. Each of the five small interfering RNA 
(siRNA) sequences, represented by a different colored dot, con-
tain complementary all ribose guide and passenger strands and 
were transfected into Hep1-6 cells at 10 nmol/l. The median value 
at each position is represented by a black bar. The dotted lines 
represent the experimental variation generated from the qPCR. 
Individual (b) 2′-O-benzyl or (c) 2′-O-CH2Py(4) were substituted 
at the indicated position on the guide strand of the duplex. Activity 
of the chemical unmodified (all ribose) siRNA is at the zero line. 
Increased mRNA degradation activity compared to an unmodified 
siRNA would result in a ratio higher than zero and would be ad-
vantageous to the siRNA and all points below the zero line have 
decreased activity.www.moleculartherapy.org
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activity of the siRNA relative to the unmodified sequence the 
ratio value is positive. siRNAs with 2′-O-benzyl had median 
values the same or better than unmodified siRNAs at posi-
tions 5, 8, 15, and 19 on the guide strand. Positions 5, 6, 
8, 10, 15, and 19 were equivalent or better than unmodified 
siRNAs for 2′-O-CH2Py(4). These data demonstrate these 
new modifications are tolerated at the same positions for mul-
tiple sequences. Our findings indicate that there is potentially 
more optimization to be done of the siRNA/Ago2 complex 
than previously realized.
2′-O-benyzl modifications enhance in vivo activity and 
duration.  We  next  assessed  2′-O-benzyl  modifications 
in vivo using the most tolerated positions from the in vitro 
data above for 2′-O-benzyl. siRNAs containing 2′-O-benzyls 
at positions 5, 8, 15, or 19 were formulated into lipid nano-
particles and delivered by intravenous tail injection into mice 
for ApoB(10162) (Figure 2). Lipid nanoparticles localize to 
the liver, where apolipoprotein B (ApoB) is highly expressed. 
The livers were harvested and ApoB mRNA levels were eval-
uated by qPCR 3 and 14 days after injection. Mice treated 
with unmodified ApoB siRNAs showed ApoB mRNA degra-
dation of 90%. siRNAs containing 2′-O-benzyls at positions 
8 or 15 had statistically significantly higher mRNA degra-
dation than the unmodified siRNA, each with 96% mRNA 
degradation at day 3 (Figure 2a). siRNAs with 2′-O-benzyls 
at positions 5 or 19 had similar activity to the unmodified 
siRNA at day 3.
Duration of activity was evaluated until day 14 for the same 
ApoB(10162) unmodified and 2′-O-benzyl modified siRNAs 
(Figure  2b).  siRNAs  containing  2′-O-benzyls  at  positions 
5, 8, or 15 had statistically significantly better target mRNA 
degradation than unmodified siRNAs with 78, 88, and 88% 
mRNA  degradation,  respectively  compared  to  unmodified 
siRNA with 64%. ApoB siRNAs with position 19 modified with 
a 2′-O-benzyl had similar activity to unmodified siRNA.
2′-O-benzyls  combined  at  positions  8  and  15  in  the 
guide  strand  increase  activity  in  vivo.  Based  on  the 
results above, 2′-O-benzyls were combined into the guide 
strand at positions 8 and 15 and tested in vivo (Figure 3). 
Three different siRNA sequences were tested: ApoB(9514), 
ApoB(10162), and Luc(80). 2′-O-benzyls at positions 8 and 
15 in ApoB(10162) had statistically significantly better mRNA 
degradation than unmodified siRNA at day 3 and 14 (Figure 
3a). While these differences may seem small, the clinical 
significance has yet to be determined for how much target 
silencing is needed to maintain a beneficial therapeutic effect. 
Another ApoB siRNA, ApoB(9514), was also tested in vivo 
with and without 2′-O-benzyls at positions 8 and 15   (Figure 
3b). At day 3, the unmodified and 2′-O-benzyl containing 
ApoB(9514) siRNAs had similar activity in vivo. However, 
unmodified ApoB(9514) siRNAs have a shorter duration of 
activity in vivo compared to ApoB(10162), with the unmodi-
fied ApoB(9514) siRNAs having no activity by day 14. This 
duration increased when the siRNAs had 2′-O-benzyls at 
positions 8 and 15, with a statistically significant increase of 
47% mRNA degradation compared to 3% from unmodified 
siRNA. A third siRNA, Luc(80) was also tested with 2′-O-ben-
zyls  (Figure  3c).    Unmodified  and  2′-O-benzyl  containing 
Luc(80) siRNAs had similar   maximal mRNA degradation at 
day 1 in vivo. However, by day 3 mRNA degradation from 
Luc(80) unmodified siRNA was 23% whereas siRNAs con-
taining 2′-O-benzyls had a statistically significant threefold 
increase of 58% mRNA degradation. The duration of activity 
for Luc(80) siRNAs containing 2′-O-benzyl at positions 8 and 
15 slowly decreased over 21 days to 0 while the unmodified 
siRNA activity was attenuated by day 11. Area under the 
curve was calculated to determine the difference in dura-
tion between Luc(80) siRNAs. The area under the curve was 
statistically  significantly  increased  for  the  Luc(80)siRNAs 
containing 2′-O-benzyls at positions 8 and 15 compared to 
unmodified siRNA (Figure 3d). These data demonstrate two 
Unmodified
Position of 2´-O-benzyl 
in guide strand
Day 3
**
100
90
80
70
60
50
58 15 19
Unmodified
Position of 2´-O-benzyl 
in guide strand
58 15 19
100
90
80
70
60
50
a
%
 
m
R
N
A
 
d
e
g
r
a
d
a
t
i
o
n
b
%
 
m
R
N
A
 
d
e
g
r
a
d
a
t
i
o
n
Day 14
** ** *
Figure 2  2′-O-benzyls demonstrate enhanced in vivo activ-
ity after intravenous (i.v.) injection. (a) Unmodified ApoB(10162) 
small interfering RNA (siRNA), siRNAs with an 2′-O-benzyl at   either 
position 5, 8, 15, or 19 were formulated into lipid nanoparticles and 
injected in mice at 3 mg/kg. The livers were harvested and ApoB 
mRNA levels were evaluated by quantitative PCR (qPCR) 72 hours 
after injection (* = student′s t-test, P < 0.05). Each dot represents 
an individual mouse and bars represent the mean and standard 
deviation  of  all  mice  per  group.  (b)  Unmodified  ApoB(10162) 
  siRNA, siRNAs with an 2′-O-benzyl at either position 5, 8, 15, or 
19 were formulated into lipid nanoparticles and injected in mice at 
3 mg/kg. The livers were harvested and apolipoprotein B (ApoB) 
mRNA levels were evaluated by qPCR at 3, 7, and 14 days after 
injection. Data are presented as the mean and s.e.m. *P < 0.05 
versus   unmodified; **P < 0.005 versus unmodified.Molecular Therapy–Nucleic Acids
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2′-O-benzyls can be incorporated into multiple siRNA guide 
strands at positions 8 and 15 with beneficial effects in dura-
tion of activity. It also indicates further optimization and SAR 
at positions 8 and 15 may be possible to bring about even 
larger increases in duration and activity in vivo.
2′-O-benzyls combined at positions 5, 8, 15, and 19 in the 
guide strand increase activity in vivo. We next wanted to 
test whether the number of 2′-O-benzyls in an siRNA would 
have a beneficial effect on in vivo activity. Since two 2′-O-ben-
zyl modifications increased in vivo activity, if an siRNA con-
tained  all  the  positions  where  2′-O-benzyl  was  tolerated, 
positions 5, 8, 15, and 19, there potentially could be an even 
greater increase in vivo activity. These four positions individu-
ally had activity comparable or better in vitro (Figure 1b) and 
in vivo (Figure 2) than the unmodified siRNA. Four incorpora-
tions of 2′-O-benyzls were tested in vivo on the guide strand 
at positions 5, 8, 15, and 19 (Figure 4). Three different siRNA 
sequences  were  again  tested:  ApoB(9514),  ApoB(10162), 
and Luc(80). Four incorporations of 2′-O-benzyl in the guide 
strand  statistically  significantly  increased  maximum  mRNA 
degradation for ApoB(10162) siRNA at day 3 in vivo (Figure 
4a), from 89 to 93%, respectively. The duration of activity, as 
measured at day 14, for the 2′-O-benzyl modified ApoB(10162) 
siRNA was comparable to the unmodified siRNA, in contrast 
to the statistically significant increase observed when there 
were only two incorporations of 2′-O-benzyl (Figures 3a and 
4a). mRNA degradation for ApoB(9514) siRNAs containing   
2′-O-benzyls at positions 5, 8, 15, and 19 at day 3 was statisti-
cally significantly increased compared to unmodified siRNA 
from 71 to 86% (Figure 4b). Duration was statistically signifi-
cantly increased at day 14 for ApoB(9514) when the siRNAs 
contained 2′-O-benzyls at positions 5, 8, 15, and 19 with 45% 
mRNA degradation compared to 3% from unmodified siRNA. 
At day 3, unmodified Luc(80) siRNAs had 31% mRNA deg-
radation compared to 81% from the siRNA with 2′-O-benzyls 
at positions 5, 8, 15, and 19 at day 3 (Figure 4c). The area 
under the curve was statistically significantly larger for Luc(80) 
siRNAs containing 2′-O-benzyl at positions 5, 8, 15, and 19 
compared to unmodified siRNAs, indicating four 2′-O-benzyl 
modifications can favorably alter the duration of an siRNA 
in vivo (Figure 4d). For multiple siRNA sequences, four incor-
porations of 2′-O-benzyl produced favorable, statistically sig-
nificant increases in maximal mRNA degradation and duration 
of siRNAs. However, four incorporations of 2′-O-benzyl in the 
guide strand did not have better activity over only two incor-
porations at positions 8 and 15. This demonstrates that while 
four incorporations can be tolerated in the guide strand, using 
the correct modification at the correct position for maximal in 
vivo benefits is crucial in the siRNA optimization process.
2′-O-CH2Py(4) modifications enhance in vivo duration. 
We next tested whether small changes in SAR would have an 
effect on the siRNA guide strand. A 2′-O-CH2Py(4) modifica-
tion, similar in size to 2′-O-benzyl, but with different structural 
and hydrogen-bonding properties, was used on the same set 
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Figure 3  In vivo evaluation of 2′-O-benzyls at positions 8 and 15 on the small interfering RNA (siRNA) guide strand. (a) Unmodi-
fied ApoB(10162), (b) ApoB(9514), and (c) Luc(80) siRNAs and the same siRNAs with 2′-O-benzyls at positions 8 and 15 were formulated 
into lipid nanoparticles and injected in mice at 3 mg/kg. The livers were harvested for Apo(9514) and ApoB(10162) mice and mRNA levels 
were evaluated by quantitative PCR (qPCR) at 3 and 14 days after injection. Luciferase mice were imaged every other day after dos-
ing. Area under the curve was calculated (d) for Luc(80) siRNAs as a measure of duration. Data are presented as the mean and s.e.m.   
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of siRNAs used throughout this study. In vitro, we observed 
positions 5, 6, 8, 10, 15, and 19 were equivalent or better 
than unmodified siRNAs for 2′-O-CH2Py(4) (Figure 1c). siR-
NAs were made with 2′-O-CH2Py(4) at positions 8 and 15, 
in order to directly compare to the 2′-O-benzyl results. siR-
NAs were also made with incorporations at positions 5, 6, 
8, 10, 15, and 19 to understand the correlation between the 
number of modifications and in vivo activity as well as the 
maximal tolerance of the guide strand for modifications (Fig-
ure 5). ApoB(10162) siRNAs were created with and without 
2′-O-CH2Py(4) and tested in vivo for mRNA degradation at 
days 3 and 14. When 2′-O-CH2Py(4) were placed at posi-
tions 8 and 15 there was a statistically significant increase 
in mRNA degradation at day 3 and 14 (Figure 5a). At day 3, 
the unmodified ApoB(10162) siRNAs had 90% mRNA deg-
radation while the siRNAs with 2′-O-CH2Py(4) at positions 8 
and 15 had 95%; and at day 14, the unmodified ApoB(10162) 
siRNAs had 68% mRNA degradation while the siRNAs with 
2′-O-CH2Py(4) had 88%. ApoB(10162) siRNAs containing six 
incorporations of 2′-O-CH2Py(4) at positions 5, 6, 8, 10, 15, 
and 19 had comparable activity to unmodified siRNA at day 
3 and 14 (Figure 5b). As with 2′-O-benzyl, this data shows 
the importance of proper placement of the modifications to 
have maximal activity gains. Interestingly, the statistically sig-
nificant increases in silencing activity over unmodified siRNA 
came from siRNAs with two incorporations of 2′-O-CH2Py(4), 
not six. While six modifications were tolerated, they only had 
the  same  in  vivo  silencing  activity  as  unmodified  siRNAs. 
These data suggest that the 2′-O-CH2Py(4) is not the optimal 
modification at all six positions and additional SAR at each 
position may be needed to confer optimal activity.
Discussion
Maximizing in vivo siRNA potency by chemical modification is 
therapeutically desirable in order to minimize the dose of deliv-
ered siRNA required for efficient RNAi, lower the cost of goods 
and increase the duration of the siRNA. We have identified and 
tested two novel 2′-O- modifications in vivo that were optimized 
specifically for use in siRNA. These modifications were toler-
ated in combination at multiple positions in the guide strand, 
with 2′-O-CH2Py(4) placed at six positions and 2′-O-benzyl at 
four positions. Increased in vivo duration was observed with 
these modifications over their unmodified counterparts.
The mechanism for the increased potency of these modifi-
cations remains to be elucidated. Since the lipid nanoparticle 
encapsulates the siRNAs and shields it from serum nucle-
ases and provides high serum stability to the siRNA regard-
less of modification status, it is unlikely that improved serum 
stability is responsible for the improved in vivo activity. Also, if 
the modifications were to confer added serum stability result-
ing in increased potency we would predict that siRNAs with 
four incorporation of 2′-O-benzyls to have more activity than 
the siRNAs with only two incorporations. However, our data 
do not support this hypothesis. In fact, the opposite occurred. 
siRNAs  with  two  chemical  incorporations  were  superior  to 
those  siRNAs  with  four  2′-O-benzyls. Therefore,  increased 
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serum stability, delivery efficiency, or uptake would probably 
not be a cause for the increased potency observed. Increased 
Ago2 binding is an additional possibility for increased potency. 
Analysis of the Ago crystal structure showed that positions 
2–6 of the guide strand form a stacked helical conformation 
and has extensive surface and charge complementarity with 
the  PIWI  domain.30,31 The  bases  at  the  5′-end,  from  posi-
tions 2–8 also contribute to target mRNA-binding energy. The 
2′-O-benzyl and 2′-O-CH2Py(4) modifications at positions 5 
or 8 may therefore play a role in the enhancing the siRNA 
conformation and interactions with Ago2 and its target. To 
examine this further, we measured siRNA binding to Ago2 via 
stem-loop PCR.32 However, these large 2′-modifications could 
not be interpreted by and were not compatible with the poly-
merases used in stem-loop PCR. No meaningful data was 
obtained. In previous work, we have also measured the Tm’s 
of  the  2′-O-benzyl modifications in the siRNA walkthrough 
and found no differences at any position between the modi-
fied and unmodified siRNAs.29
The chemical modified ribose rings have the potential to 
be further optimized. We have also demonstrated that siR-
NAs can tolerate 2′-O-benzyl and 2′-O-CH2Py(4) modifica-
tions that are larger than conventional modifications such as 
2′-OMe and 2′-F. However, even between 2′-O-benzyl and 
2′-O-CH2Py(4)  there  were  positional  preferences  where 
2′-O-CH2Py(4)  was  tolerated  at  positions  6  and  10  and 
benzyl was not. The small change of a carbon to nitrogen 
provided  additional  benefits  at  positions  6  and  10  in  an 
siRNA that benzyl was unable to provide. Yet, 2′-O-benzyl 
and 2′-O-CH2Py(4) modifications are limited and more SAR 
can be done at the specific positions they are tolerated to 
understand and harness the interactions with Ago2, such as 
hydrogen bonding and lipophilicity, to achieve maximal siRNA 
activity. 2′-O-benzyl and 2′-O-CH2Py(4) can potentially have 
their  ortho-,  meta-,  and  para-carbons  further  modified  to 
understand  the  constraints  of  every  position  in  an  siRNA 
when it interacts with Ago2. There is the potential to alter 
the length and width of the modification using different ring 
sizes. Once the chemical space is identified, each position 
can have its own unique modification tailor-fit for maximum 
potency and the combinations of such modifications will allow 
the generation of superior siRNAs that can form the basis for 
potent and safe siRNA therapeutics in the near future.
One  of  the  most  critical  issues  in  developing  modified 
siRNAs is the placement of the modification in the duplex. 
The wrong modification at the wrong position can obliterate 
activity. We have shown a simple walkthrough of a modifica-
tion successfully predicts the positions to use in combina-
tions. These combinations improved siRNA performance in 
vivo. In addition, more of a modification does not equal bet-
ter activity. Four 2′-O-benzyl modifications on an siRNA had 
increased siRNA activity in vivo but were not better than only 
two 2′-O-benzyls at positions 8 and 15. A systematic study 
is required covering as much chemical space as possible to 
understand the role of modifications at each position of the 
siRNA guide strand and its interactions in the RISC complex. 
The strategic placement of modifications at each position will 
be critical for optimal siRNA design.
The universally applicability of a modification pattern has 
not emerged, mostly due in part to 2′-OMe and 2′-F maintain-
ing activity at many positions on the guide strand which allows 
for many different combinations to be created and have activ-
ity. In this study, multiple sequences were used and the same 
positions in all of them, both individually and in combination, 
had similar activity in vitro and in vivo. The findings from this 
set of siRNA sequences used in vitro were also able to be 
applied to the Luc(80) sequence that was not included origi-
nally in the walkthrough data. The Luc(80) siRNA had similar 
results to the ApoB sequences also tested in vivo, indicat-
ing that using a small test set of sequences can potentially 
identify the specific positions a modification should be placed 
in any siRNA of interest. As more specific modifications are 
created, a pattern that is applicable to any siRNA for maximal 
potency, stability and specificity will emerge.
siRNA design will require modifications to balance between 
delivery, potency, stability, and pharmacokinetics properties. 
Clear mechanistic information is needed about how best to 
select  and  modify  siRNAs  for  a  given  target  and  applica-
tion. Expansion of novel modifications available for the guide 
strand will be useful for future therapeutics.
Materials and methods
2  ′-O-benzyl and 2  ′-O-CH2Py(4) synthesis. The 2′-O-benzyl 
and 2′-O-CH2Py(4) modified phosphoramidites were synthe-
sized using procedures analogous to those described.29 All 
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Figure 5  In vivo duration of 2′-O-CH2Py(4) on the small in-
terfering RNA (siRNA) guide strand. Unmodified ApoB(10162) 
siRNA and the same siRNAs with 2′-O-CH2Py(4) at positions (a) 
8 and 15 or (b) 5, 6, 8, 10, 15, and 19 on the guide strand were 
formulated into lipid nanoparticles and injected in mice at 3 mg/
kg. The livers were harvested and mRNA levels were evaluated by 
quantitative PCR (qPCR) at 3 and 14 days after injection. Data are 
presented as the mean and s.e.m. *P < 0.05 versus unmodified.www.moleculartherapy.org
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nonhydrolytic reactions, unless indicated otherwise were car-
ried out in dry solvents purchased from Aldrich (St. Louis, MO). 
High-performance  liquid  chromatography  analyses,  except 
for the amidites, were performed at 60  °C using an Agilent 
Zorbax Eclipse Plus C18, 2.1 × 50  mm, 1.8 micron column, 
at 0.8  ml/minute flow rate, eluted with a gradient (5–95%) of 
acetonitrile and water with formic acid (0.1%) as a modifier. 
The amidites were analyzed using a Supelco Ascentis C18, 
100 × 4.6  mm, 2.7 micron column and ammonium formate 
(3 mmol/l) as a modifier, under otherwise identical conditions. 
UV traces were recorded at 220 nm and mass spectra were 
obtained  using  an  Agilent Technologies  6140  Quadrupole 
LC/MS mass spectrometer in both positive and negative ion 
mode. NMR spectra were recorded on a Varian Unity 600, 
500, or 400 spectrometers.
Oligo  synthesis  and  sequences.  Chemically  modified 
  siRNAs contained either ribo (r), deoxy (d), inverted aba-
sics (iB) or O-methyl (ome) 2′ modifications as described 
previously.33 The siRNA sequences and modification are as 
follows from 5′-3′:
Luciferase(80) unmodified siRNA:
  Passenger: iB;rA;rU;rA;rA;rG;rG;rC;rU;rA;rU;rG;rA;rA;rG; 
rA;rG;rA;rU;rA;dT;dT;iB
  Guide: rU;rA;rU;rC;rU;rC;rU;rU;rC;rA;rU;rA;rG;rC;rC;rU;rU; 
rA;rU;dT;dT
ApoB(9514) unmodified siRNA:
  Passenger: iB;rC;rU;rU;rU;rA;rA;rC;rA;rA;rU;rU;rC;rC;rU; 
rG;rA;rA;rA;rU;omeU;omeU;iB
  Guide: rA;rU;rU;rU;rC;rA;rG;rG;rA;rA;rU;rU;rG;rU;rU;rA;rA;
rA;rG;omeU;omeU
ApoB(10162) unmodified siRNA:
  Passenger:  iB;rC;rA;rA;rG;rU;rG;rU;rC;rA;rU;rC;rA;rC;rA; 
rC;rU;rG;rA;rA;omeU;omeU;iB
  Guide: rU;rU;rC;rA;rG;rU;rG;rU;rG;rA;rU;rG;rA;rC;rA;rC;rU; 
rU;rG;omeU;omeU
PHD2(196) unmodified siRNA:
  Passenger: iB;rC;rA;rU;rU;rG;rA;rA;rC;rC;rC;rA;rA;rA;rU;rU;
rU;rG;rA;rU;omeU;omeU;iB
  Guide: rA;rU;rC;rA;rA;rA;rU;rU;rU;rG;rG;rG;rU;rU;rC;rA;rA;
rU;rG;omeU;omeU
PHD2(384) unmodified siRNA:
  Passenger:  iB;rC;rA;rG;rU;rC;rA;rG;rC;rA;rA;rA;rG;rA;rC; 
rG;rU;rC;rU;rA;omeU;omeU;iB
  Guide: rU;rA;rG;rA;rC;rG;rU;rC;rU;rU;rU;rG;rC;rU;rG;rA;rC; 
rU;rG;omeU;omeU
Transfection and qPCR. Transfection and qPCR for in vitro 
and  in  vivo  studies  were  done  as  described  previously.34 
Hepa1-6 cells were cultured in Dubelco ’s modified Eagle’s 
medium (Mediatech Cellgro, Manassas, VA) containing 10% 
serum. Cells were plated in a 96-well plate (3,500 cells/well) 
and were transfected 24 hours after plating in Opti-MEM I 
Reduced Serum Media (Gibco, Grand Island, NY) and Lipo-
fectamine RNAiMax reagent (Invitrogen, Grand Island, NY) 
for  a  final  concentration  of  10  nmol/l  siRNA  for  the  initial 
screening.  For  IC50  curves  the  final  concentration  ranged 
from 0.15 pmol/l to 160 nmol/l along a 12-point titration curve. 
Approximately 24 hours after transfection, cells were washed 
with phosphate-buffered saline and lysed in Cells-to-CT Lysis 
Buffer (Ambion, Grand Island, NY) with rDNase I (RNase-
free) added. Stop solution (Ambion) was used to halt the reac-
tion. Reverse transcription-PCR was performed using 7 µl of 
cell lysate in 2× RT buffer with 20× RT Enzyme Mix (Ambion) 
added. Conditions were as follows: 37  °C for 60 minutes and 
95  °C for 5 minutes. mRNA levels were detected by qPCR 
with target-specific probes from Applied Biosystems. All com-
plementary DNA samples were added to a 10-µl reaction vol-
ume with the following cycling conditions: 2 minutes at 50  °C, 
10 minutes at 95  °C, followed by 40 cycles of 15 seconds at 
95  °C and 1 minute at 60  °C. qPCR was assayed using an 
ABI Prism 7900 sequence detector using 2× Taqman Gene 
Expression Master Mix (Applied Biosystems). GAPDH mRNA 
levels were used for data normalization.
siRNA  formulation.  Lipid  nanoparticles  were  made  using 
the cationic lipid 2-{4-[(3b)-cholest-5-en-3-yloxy]-octyl}-N,N-
dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-
amine (Merck and Co., Whitehouse Station, NJ), cholesterol 
(Northern Lipids, Burnaby, British Columbia, Canada), and 
monomethoxypolyethyleneglycol-1,2-dimyristoylglycerol 
(NOF, Tokyo, Japan) at a 60:38:2 mol/l ratio, respectively.
In vivo. C57BL/6 male mice 20–23  g were purchased from 
Taconic Farms. Mice were injected intravenously with 200  µl 
containing 3  mg/kg siRNA formulated in a lipid nanoparticle. 
Four mice per group were sacrificed at indicated time points 
following  siRNA  injection.  Livers  were  harvested  and  pro-
cessed to assess target mRNA levels by qPCR as described 
above. To determine statistical significance a Student’s t-test 
was used to obtain P values. A P value was considered “sta-
tistically significant” if it was <0.05 and was denoted on the 
bar graphs: *P < 0.05; **P < 0.005; ***P < 0.0005. The use 
of the words “comparable” or “similar” in the text refers to the 
lack of statistical significance.
Luciferase mouse model. The luciferase mouse model and 
imaging measurements and analysis were done as described 
previously.32
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